We investigated for the first time, to the best of our knowledge, the prognostic value of hematological markers within the 5 primary glioma molecular groups and found that for lower-grade gliomas, high NLR and MLR predicted worse survival in the IDH and TERT mutations group, high NLR and PLR predicted worse survival in the IDH mutation only and TERT mutation only groups, and high NLR was associated with shorter survival in the triple-negative group. This evidence concerns the gene IDH1 and central nervous system cancer.